Torabi Nezhad Simin, Malekmakan Leila, Mashayekh Mina, Karamifar Nazanin, Tadayon Taraneh
Shiraz Nephro-urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Sattarkhan Street, Dena Hospital, Shiraz, Iran.
Caspian J Intern Med. 2024 Aug 30;15(4):606-614. doi: 10.22088/cjim.15.4.606. eCollection 2024 Fall.
Bladder cancer is the 5 most prevalent cancer among Iranian men. Finding prognostic markers to predict behavior of this cancer can help us to choose the best treatment for patients from the first place. We aimed to evaluate the correlation of immunohistochemical markers with tumor stage, grade and prognosis of disease.
In this study, we reassessed the specs of proven UC among Iranian patients. Sixty specimens were collected, contained of 30 low grade and 30 high grade urothelial carcinomas. All slides were assessed by immunohistochemistry study for p21, p27, Her-2/, E-cadherin, and CD10. Data were analyzed by SPSS 18.0 and a -value < 0.05 was considered significant.
We evaluated 60 patients in this study with mean age of 66±11 years and majority of them are men. High expression of p27 showed significant correlation with LGUC (=0.030). HGUC related with high expression of Her-2/, CD10 and aberrant expression of E-Cadherin (<0.0001). Aberrant E-Cadherin and high expression of CD10 are associated with higher tumor stage (=0.000). CD10 intensity was the only immunohistochemical markers to predict prognosis (=0.010).
In the present study, CD10 intensity is the only marker that directly predicts the prognosis. The higher intensity leads to poor prognosis (recurrence or metastasis). More studies must be done in this aspect to resolve the controversies and clarify the role of immunohistochemical markers in predicting BC behaviors.
膀胱癌是伊朗男性中第五大常见癌症。寻找预测这种癌症行为的预后标志物有助于我们从一开始就为患者选择最佳治疗方案。我们旨在评估免疫组化标志物与肿瘤分期、分级及疾病预后的相关性。
在本研究中,我们重新评估了伊朗患者中已证实的尿路上皮癌的样本。收集了60个样本,其中包括30例低级别和30例高级别尿路上皮癌。所有切片均通过免疫组化研究检测p21、p27、Her-2/、E-钙黏蛋白和CD10。数据采用SPSS 18.0进行分析,P值<0.05被认为具有统计学意义。
本研究评估了60例患者,平均年龄为66±11岁,大多数为男性。p27的高表达与低级别尿路上皮癌显著相关(P=0.030)。高级别尿路上皮癌与Her-2/、CD10的高表达及E-钙黏蛋白的异常表达相关(P<0.0001)。E-钙黏蛋白异常和CD10高表达与更高的肿瘤分期相关(P=0.000)。CD10强度是唯一可预测预后的免疫组化标志物(P=0.010)。
在本研究中,CD10强度是唯一直接预测预后的标志物。强度越高,预后越差(复发或转移)。在这方面必须进行更多研究以解决争议并阐明免疫组化标志物在预测膀胱癌行为中的作用。